Distribution of visceral leishmaniasis (VL) cases in East Africa. a This satellite image is taken from Google Maps. b The distribution of VL for each region or state within East African countries [5, 27, 35, 36]. The largest affected area in terms of number of cases is the eastern region of Sudan and neighboring Ethiopia (Area 1), followed by South Sudan (Area 2), Darfur and Western Sudan (Area 3), and Somalia (Area 4), and Kenya with North East Uganda (Area 5) - (researchgate.net)
A shorter, and less toxic treatment for people with visceral leishmaniasis was shown to be effective thanks to a study conducted in Eastern Africa by the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) and its partners.
The results were published in The Clinical Infectious Diseases journal. The new treatment consists of a combination of two drugs: miltefosine (MF), the only oral drug available for leishmaniasis treatment, and paromomycin (PM), an injectable antibiotic. ‘This new treatment is great news for the thousands of patients affected by visceral leishmaniasis in the region.It will eliminate one painful and toxic injection from the treatment and is therefore safer for those affected,’ said Prof. Ahmed Musa, Deputy Vice Chancellor at the University of Khartoum and Principal Investigator of the clinical trial conducted in Sudan. Leishmaniasis is the deadliest parasitic killer after malaria.
Its most severe form, visceral leishmaniasis (VL), is fatal if left untreated. There are 50,000 to 90,000 new cases of the disease annually, with the highest number of cases worldwide reported in Eastern African countries: Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan, and Uganda.
The disease affects people in resource-limited settings, arid and semi-arid areas. Half of them are children under 15. Leishmaniasis is also a climate-sensitive disease, and its impact could get worse.Therefore, if not addressed, the most vulnerable will continue to suffer.
The current first-line treatment in Eastern Africa consists of paromomycin (PM), an injectable antibiotic used in combination with sodium stibogluconate (SSG), administered either through injection or intravenously. It remains sub-optimal, as patients may suffer from rare but heavy side effects, such as cardiotoxicity, hepatotoxicity, and pancreatitis associated with SSG.
The treatment is also difficult to administer since patients must endure two painful injections every day for 17 days.
“The current treatment has significant socio-economic impact as patients are forced to stay in hospitalfor extended periods and have to miss work or school. With the new treatment patients will spend lesstime in hospital,” said Prof. Musa.
The results announced today stem from a clinical trial initiated in 2017 in Kenya, Ethiopia, Sudan, and Uganda by the AfriKADIA Consortium with funding from The European & Developing Countries Clinical Trials Partnership (EDCTP). The study compared a new combination of two drugs, miltefosine and paromomycin, given for 14 days, to the standard of care of sodium stibogluconate and paromomycin given for 17 days.Results show that the MF+PM treatment is over 91% effective in treating visceral leishmaniasis. Whilethis treatment is just as effective as the existing treatment, it has the advantage of reducing hospitalization time by 18% and removing one painful daily injection and the potential life-threateningtoxicity associated with sodium stibogluconate.
It is therefore more patient-friendly. Children, who are the majority of visceral leishmaniasis patients – were also shown to respond very well to this new treatment and will particularly benefit from it.
The treatment also lowers the risk of the occurrence of post-kala-azar dermal leishmaniasis (PKDL) – a common complication of visceral leishmaniasis that appears after treatment mainly in Sudan andEthiopia – to 4 %, lower than 20.9% if treated by SSG+PM. This is important because PKDL patients are a source of infection to sandflies, therefore reducing cases of PKDL will reduce transmission.
“The new combination treatment signifies a historical step forward for dreadfully neglected patientpopulations. After many decades we have finally included an oral treatment to the regimen, reducingsevere side effects and the burden on health systems thanks to decreased hospitalization time,” said Dr Monique Wasunna, DNDi Eastern Africa Regional Director in Nairobi, Kenya. Efforts have begun to share the study results with stakeholders in the region to facilitate the adoption of the new combination, so that patients can access the treatment soon.
“We are delighted with the positive results from this clinical trial. It will contribute to our strategic goal of reducing morbidity due to leishmaniasis by 60% by 2025,’ said Dr Patrick Amoth, Director General for Health at the Ministry of Health, Kenya.“I have asked my Technical Advisory Group to review the evidence provided by DNDi and make recommendations on the adoption of the new treatment.” DNDi and its partners are working towards finding even better treatments that would completely remove the need for injectables and would be better adapted to local conditions.
“The journey is not over yet. DNDi and its partners will be beginning clinical trials for new, promising, all-oral treatments for leishmaniasis soon,’ said Dr Fabiana Alves, Director of Neglected Tropical Diseases leishmaniasis[1] and mycetoma Cluster at DNDi. ‘Our goal is to radically transform treatments for visceral leishmaniasis by developing patient-friendly oral therapies that are affordable, safe, and effective in patients in all regions.”
References
- ^ Neglected Tropical Diseases leishmaniasis (dndi.org)
Newer articles:
- South Sudan, Djibouti sign MoU to lay fibre optic cable - 29/09/2022 11:00
- South Sudan parliament passes 1.4 trillion SSP budget - 29/09/2022 00:30
- South Sudan, African Development Bank launch project to boost food production - 29/09/2022 00:25
- South Sudan to set up special court for cybercrime - 29/09/2022 00:20
- South Sudan violence proliferating, warn independent rights experts - 29/09/2022 00:10
Older news items
- African Union Launches Push for Universal Ratification of Anti-Graft Convention - 29/09/2022 00:00
- South Sudan: Health ministry, WHO install Ebola surveillance teams at border points with Uganda - 28/09/2022 03:03
- Report exposes U.N. camp abuses, but research shows justice is elusive - 28/09/2022 02:00
- Sudan traditional wind instrument trumpets harvest time - 28/09/2022 01:11
- South Sudan should disarm civilians – the evidence shows this improves security - 27/09/2022 11:28
Latest news items (all categories):
- The Collo Kingdom Remains Underdeveloped: Five Hundred Years Later! - 03/02/2025 12:57
- Attack on South Sudan cattle camps kills 35 - 03/02/2025 12:46
- في صفقة مثيرة.. الإمارات تشتري نفط الجنوب في باطن الأرض لمدة 20 عامًا - 03/02/2025 12:42
- South Sudan: Can oil production save the economy? - 30/01/2025 19:27
- 20 oil workers and crew die in South Sudan plane crash - 30/01/2025 19:20
Random articles (all categories):
- Marel donating EUR 1 million to Red Cross to improve food security in South Sudan - 26/11/2020 07:30
- Kerry Calls for Speedy Deployment of South Sudan Protection Force - 22/08/2016 11:46
- Sudan revolutionaries urge reform of the armed forces - 24/09/2021 02:43
- Sudan hands out more than 500 chrome licenses in border state - Reuters - 10/09/2012 15:01
- WHO says South Sudan polio free now - 19/06/2020 11:53
Popular articles:
- Who is the darkest person in the world, according to Guinness World Record? - 25/10/2022 02:34 - Read 67644 times
- No oil in troubled waters - 25/03/2014 15:02 - Read 22360 times
- School exam results in South Sudan show decline - 01/04/2012 17:58 - Read 21558 times
- Top 10 weakest currency exchange rates in Africa in 2023 - 19/07/2023 00:24 - Read 19208 times
- NDSU student from South Sudan receives scholarship - In-Forum - 29/09/2012 01:44 - Read 19199 times